FDA cautiously backs anemia drugs. Statin drugs may lower the risk of colon cancer. Print E-mail
By Mary Davila   
Monday, 18 October 2010 18:50
Below is a look at some of the headlines for companies that made news in the healthcare sector on October 18, 2010.
FDA cautiously backs anemia drugs - The U.S. Food and Drug Administration should not restrict the use of popular anemia drugs sold by Amgen Inc (NASDAQ:AMGN) and Johnson & Johnson (NYSE:JNJ) in patients with chronic kidney disease, U.S. medical advisers.

The FDA's panel of outside experts said the drugs, which include Amgen's Aranesp and Epogen and J&J's Procrit, clearly have safety issues but that more data was needed.

The Amgen and J&J drugs are expected to generate $4.5 billion in sales in 2010, although sales have declined in recent years over concerns about overuse in certain patients and reimbursement restrictions.


Statin drugs may lower the risk of colon cancer by as much as 12 percent - The longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.

Many researchers have found that statin drugs, which include Pfizer Inc's (NYSE:PFE) Lipitor and AstraZeneca Plc's (NYSE:AZN) Crestor, have effects far beyond lowering cholesterol and reducing the risk of heart disease.
Here are other companies that made news on Monday:

3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release unaudited financial results for the third quarter ended September 30, 2010 after the Nasdaq Stock Exchange closes on Monday, November 15, 2010 at 8:00pm(Eastern).
Abaxis, Inc. (Nasdaq:ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the second quarter of fiscal year 2011, ended September 30, 2010. The call will be at 4:15 p.m. ET on Tuesday, October 26, 2010.
Amarin Corporation plc (Nasdaq:AMRN) today announced that Dr. Declan Doogan, Chief Medical Officer, is scheduled to present on Amarin's behalf at the NewsMakers in the Biotech Industry Conference on Friday, October 22, 2010 at 2:00 pm.
Amgen (Nasdaq:AMGN) will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) patients at today's meeting of the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC).
BioMed Realty Trust, Inc. (NYSE:BMR) today announced it will report results for its third quarter ended September 30, 2010 after the market closes on Wednesday, November 3, 2010.
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today reported diagnostic net sales of $1,177,712 for the first quarter of fiscal 2011 ended August 31, 2010, compared to diagnostic net sales of $1,148,521 for the first quarter of fiscal 2010.
Depomed, Inc. (NASDAQ: DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the 17th Annual Meeting of NewsMakers in the Biotech Industry Conference on Friday, October 22, 2010 at 9:30 am EST, and at the Oppenheimer 21st Annual Healthcare Conference on Wednesday, November 3, 2010 at 2:45 pm EST, both in New York City.
Edwards Lifesciences Corporation (NYSE:EW), the global leader in the science of heart valves and hemodynamic monitoring, plans to announce its operating results for the quarter ended September 30, 2010 after the market closes on Monday, October 25, 2010 and will host a conference call at 5:00 p.m. ET that day to discuss its results.
Generex Biotechnology Corporation (Nasdaq: GNBT) announced today that Dr. Joseph Rubinfeld, an independent scientific advisor to the Company and a member of the Company's Scientific Advisory Board
Robert T. McNally, Ph.D., president and CEO of GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board:GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has contributed an article on the search for an HIV vaccine to the October 15 issue of Genetic Engineering & Biotechnology News (GEN).
Given Imaging Ltd. (NASDAQ: GIVN) today announced two new studies underscoring the value of Bravo® pH Monitoring in patients with gastroesophageal reflux disease (GERD).
Rural/Metro Corporation (NASDAQ: RURL) announced today that it will report results for its fiscal 2011 first quarter ended September 30, 2010 on Monday, November 8, 2010 before the opening of the stock markets. 
Given Imaging Ltd. (NASDAQ: GIVN) today announced new data highlighting the clinical value of PillCam SB capsule endoscopy in disease management.
Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that the company has completed the previously announced institutional transaction and has successfully been funded.
HORIZON HEALTH INTERNATIONAL CORP. (PINKSHEETS:HZHI) the Company) Mr. Rocco Di Fruscia, President of Horizon Health International Corp., is pleased to announce the appointment of Dr. Max Arella to Chairman of the Board of Directors of the Company.
Kendle (Nasdaq:KNDL) announced today it will release its third quarter 2010 financial results after the market closes on Monday, Nov. 8, 2010.
NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced plans to pursue a U.S. label expansion for Qutenza® (capsaicin) 8% patch to include patients with painful HIV-associated neuropathy (HIV-AN, also referred to as HIV-distal sensory polyneuropathy (HIV-DSP).
Neuralstem, Inc. (NYSE Amex:CUR) updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.
Neurocrine Biosciences, Inc. (Nasdaq:NBIX) announced today that it has successfully completed a second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854.
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP) today announced that the first patient has been infused in its FDA-cleared Phase I/II human clinical trial of Alpha-1 antitrypsin ("AAT") in recently diagnosed Type 1 diabetics at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Denver Anschutz Medical Campus.
OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) today announced that it is commencing a public offering of its common stock and warrants to purchase shares of its common stock.
Rural/Metro Corporation (NASDAQ: RURL) announced today that its wholly owned subsidiaries, Rural/Metro Operating Company, LLC and Rural/Metro (Delaware) Inc., intend to commence a private offering to eligible purchasers, subject to market and other conditions, of $200 million principal amount of Senior Notes due 2018 (the "Notes"), and intend to negotiate a $175 million secured financing to replace its existing senior secured revolving credit, term loan and letter of credit facilities.
Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, announced today that it has regained compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market.
Transcept Pharmaceuticals, Inc. (Nasdaq:TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present a general business overview at the Newsmakers in the Biotech Industry Conference in New York on October 22, 2010 at 10:30 a.m. EDT.
UV Flu Technologies, Inc. (OTCBB:UVFT) (the "Company") is pleased to announce that it has been selected as the only air purification medical device to be listed in the Infection Control Segment of the prestigious UK-based opinion and analysis industry publication "Public Service Review."
Rural/Metro Corporation (NASDAQ: RURL), a leading provider of ambulance and private fire protection services, today is launching a tender offer and consent solicitation for its outstanding 12¾% Senior Discount Notes due 2016 (the "Notes").
WellTek, Inc. (OTCBB: WTKN), a global health, fitness and wellness company, announced today that its subsidiary WellCity, the premier online destination for those into health and wellness, formed a strategic alliance with Clarus Transphase Scientific, Inc. and launched Clarus Q-Link products on its social network, wellcity.com.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter